Oculis Prices $100 Million Offering of Ordinary Shares
Deal News | Feb 14, 2025 | VI Partners AG
Oculis Holding AG, a biopharmaceutical company specializing in treatments for ophthalmic and neuro-ophthalmic diseases, has announced the pricing of their latest offering of 5,000,000 ordinary shares at $20.00 per share. This oversubscribed offering aims to raise $100 million, with closing expected by February 18, 2025. The proceeds are earmarked for advancing the company's clinical development pipeline, bolstering its financial health, and supporting the development of Privosegtor (OCS-05), a neuroprotective candidate. BofA Securities and Leerink Partners manage the offer, with Pareto Securities and Arctica Finance playing key advisory roles. The offering is registered with the SEC and details are accessible on their website. Oculis, drawing support from Vi Partners, is positioned at the forefront of innovative eye care solutions globally.
Sectors
- Biopharmaceuticals
- Venture Capital
- Finance
Geography
- Switzerland – Oculis is headquartered in Switzerland and VI Partners is a Swiss venture capital firm.
- United States – The Offering is made pursuant to a registration statement with the U.S. SEC, and involves U.S.-based financial institutions.
- Iceland – Oculis has operational presence in Iceland.
Industry
- Biopharmaceuticals – Oculis is involved in the biopharmaceutical industry, developing treatments for ophthalmic and neuro-ophthalmic diseases.
- Venture Capital – VI Partners, a venture capital firm, supports innovative healthcare companies like Oculis.
- Finance – The financial undertakings involve investment banking, securities, and corporate finance services for the Offering.
Financials
- $100 million – Total gross proceeds expected from the Offering.
- $20.00 per share – The price at which the ordinary shares are being offered.
- 5,000,000 shares – The number of ordinary shares being offered.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Oculis Holding AG | Target | Company | A global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases. |
| VI Partners AG | Investor | Company | A Swiss venture capital firm investing in innovative technology and healthcare companies. |
| BofA Securities | Joint Bookrunner | Company | An investment banking arm of Bank of America, managing the Offering. |
| Leerink Partners | Joint Bookrunner | Company | A healthcare-focused investment bank involved in the Offering. |
| Pareto Securities | Lead Manager | Company | A provider of financial services acting as lead manager for the Offering. |
| Arctica Finance | Financial Advisor | Company | A financial advisory firm involved in the Offering. |
| U.S. Securities and Exchange Commission (SEC) | Regulatory Body | Government | The U.S. government agency that regulates the securities industry, under which the Offering is registered. |